A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

NCT02161224 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

PK of FG-4592
Hepatic Insufficiency
Healthy Subjects

Interventions

DRUG: FG-4592

Sponsor

Astellas Pharma Europe B.V.

Collaborators

[object Object]